$CIIT·8-K

Tianci International, Inc. · Jun 18, 4:30 PM ET

Compare

Tianci International, Inc. 8-K

Research Summary

AI-generated summary

Updated

Tianci International Announces $4.9M Registered Unit Offering with Warrants

What Happened
Tianci International, Inc. (CIIT) filed an 8‑K on June 18, 2026 reporting the closing of a registered offering. The company sold 4,055,000 Units at $0.81 each and 2,000,000 Pre‑funded Units at $0.809 each, generating approximately $4.9 million in gross proceeds (before placement agent fees and offering expenses). The Units include one share of common stock plus one Common Warrant; Pre‑funded Units include a pre‑funded warrant (exercise $0.001) and one Common Warrant. The offering was made under an S‑1 registration statement declared effective June 15, 2026.

Key Details

  • Gross proceeds: approximately $4,902,550 before fees and expenses; net proceeds intended for working capital and general corporate purposes.
  • Warrant terms: Common Warrants exercisable immediately at $0.81 per share for three years; Pre‑funded Warrants exercisable at $0.001 (subject to ownership limits). Common Warrants include anti‑dilution and adjustment mechanisms with a minimum floor exercise price of $0.296 (adjusted for splits/dividends).
  • Placement agent: Maxim Group LLC; fee equal to 7% of gross proceeds plus up to $100,000 reimbursable expenses; Placement Agent was issued warrants to buy up to 302,750 shares (exercise $0.81, exercisable after 180 days, expire in 3 years).
  • Restrictions and lock‑ups: Company agreed to a 30‑day limitation on issuing other stock or stock equivalents and a 3‑month restriction on variable‑rate financings; directors and officers agreed to 90‑day lock‑ups.

Why It Matters
This financing provides Tianci with fresh capital (about $4.9M gross) to support operations and general corporate needs, which can help short‑term liquidity. However, the attached warrants and placement agent warrants create potential future dilution if exercised, and the Common Warrants contain anti‑dilution adjustments that could change exercise prices and share counts. Investors should note the placement agent fee (7%) and the short‑term limitations on additional financings, which affect the company’s near‑term ability to raise more capital.

Loading document...